NASH frontrunner Intercept Pharma presented a secondary analysis of its Regenerate study that found that treatment with Ocaliva led to “early and consistent improvements” in a range of noninvasive tests. More: Can noninvasive tests advance NASH diagnostics? Intercept analysis suggests
read moreJust two days before Amarin faces a pivotal FDA advisory committee to expand its label for fish-oil derivative Vascepa, the FDA has some questions about the key trial’s placebo control—namely, whether it skewed the drug’s “landmark” cardiovascular outcomes results. More: Will mineral-oil
read moreAs the immunology market gets even more crowded, drugmakers are eyeing new indications to expand their reach. Now, Novartis’ Cosentyx and Eli Lilly’s IL-17A rival med Taltz have rolled out detailed data in non-radiographic axial spondyloarthritis. More: Novartis' Cosentyx, Eli
read moreLonza, which has been expanding its cell manufacturing operation but still faces challenges in other parts of its business, will have to face those with a new CEO. Marc Funk is leaving after less than a year in the top
read moreThe money will go towards a potential new therapy and project, seeking to discover new ways that may prevent brain cell death. More: Parkinsons UK granted £200,000 for Virtual Biotech Source: News
read more24-week data from the clinical trial showed at least a 20% improvement in disease signs and symptoms compared to placebo. More: Tremfya hits endpoints in psoriatic arthritis study Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals